Go to the list of all blogs
Allana's Avatar
published in Blogs
Jul 26, 2026
Synopsys (SNPS) Stock Slides -17.8% Over 30 Days: Drivers Behind the Move and What Comes Next

Synopsys (SNPS) Stock Slides -17.8% Over 30 Days: Drivers Behind the Move and What Comes Next

Key Takeaways

  • Synopsys shares fell approximately 17.8% over the last 30 days, dropping from $454.34 on June 26 to $373.47 by July 24, amid a confluence of company-specific and broader market headwinds.
  • A May 27 earnings beat-and-raise paradoxically fueled the selloff, as investors interpreted restrained full-year guidance and decelerating IP licensing growth as cautionary signals.
  • The company's July decision to sunset legacy manufacturing process-control software, while strategically refocusing on AI-driven design tools, introduced near-term uncertainty among major chipmaker clients.
  • A broad semiconductor selloff on July 17 accelerated losses, with SNPS shedding 7.9% in a single session alongside a 2.2% Nasdaq decline.
  • Analyst consensus remains a "Moderate Buy" with an average price target of approximately $570, implying significant upside from current levels, though technical indicators signal deeply oversold conditions.
  • Over the broader quarter, the stock has retreated markedly from the mid-$490s range as the market continues to reassess Synopsys' post-Ansys acquisition growth and margin trajectory.

Synopsys Company Overview and Market Position

Synopsys, Inc. is a dominant provider of electronic design automation (EDA) software and semiconductor intellectual property (IP) used to design, verify, and manufacture integrated circuits and complex systems-on-chip (SoCs). Its tools enable chipmakers to simulate, synthesize, and validate increasingly complex architectures before production begins. The company occupies a near-duopoly position in EDA alongside Cadence Design Systems, with deep integration into customer workflows that create substantial switching costs. The completed $35 billion acquisition of Ansys in late 2024 expanded Synopsys' reach into multiphysics simulation spanning structural, fluid, thermal, and electromagnetic analysis, broadening its addressable market well beyond chip design into automotive, aerospace, and industrial applications. With a market capitalization of approximately $71.5 billion and institutional ownership exceeding 85%, Synopsys is closely watched by investors as a bellwether for semiconductor R&D spending and AI infrastructure demand.

SNPS Stock Price Performance: Last 30 Days vs. the Quarter

Over the last 30 calendar days, SNPS declined from a closing price of $454.34 on June 26 to $373.47 on July 24, representing a decline of approximately 17.8%. The descent was not gradual; the stock experienced an accelerating selloff through mid-July, punctuated by a 7.9% single-day plunge on July 17 when shares dropped from $417.03 to $384.24. By late July, SNPS was trading roughly 41% below its 52-week high of $651.73 reached in July 2025, with the Relative Strength Index falling to deeply oversold territory near 22.5.

The quarterly picture is similarly stark. From trading around the $495–$500 range in late May following the company's fiscal Q2 earnings release, the stock has steadily deteriorated. The 50-day moving average sits at approximately $456, while the 200-day moving average hovers near $455 — both significantly above the current trading price, indicating sustained technical weakness. The stock's trajectory over the quarter reflects a market that has progressively repriced Synopsys as integration costs, margin concerns, and strategic repositioning have weighed on investor conviction.

What Drove SNPS Stock Price in the Last 30 Days

Multiple catalysts converged to drive Synopsys lower over the past month. The most significant originated with the company's fiscal Q2 2026 earnings report on May 27, where revenue of $2.28 billion and non-GAAP EPS of $3.35 both exceeded consensus estimates. Despite the headline beat, management's decision to raise full-year guidance only to roughly the midpoint of analyst expectations — rather than delivering a more aggressive upward revision — was interpreted as a signal of caution around second-half demand. Investors zeroed in on decelerating growth in the high-margin IP licensing business, which carries disproportionate weight in Synopsys' profitability profile. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

In early July, Reuters reported that Synopsys had informed over a dozen major semiconductor manufacturers — including Samsung Electronics, SK Hynix, Kioxia, and Qorvo — that it would discontinue a portfolio of legacy manufacturing process-control software products. While the company framed this as a strategic reallocation toward higher-margin AI-driven design tools, the announcement introduced near-term execution uncertainty and raised questions about potential revenue disruption.

A broad-based semiconductor selloff on July 17 compounded the pressure, with the Nasdaq falling 2.22% as investors rotated out of concentrated AI and technology positions. SNPS was caught in the downdraft, shedding nearly 8% in a single session. Insider selling also drew attention: CFO Shelagh Glaser sold shares at $450.02 on June 12, and CEO Sassine Ghazi sold shares at $458.96 on June 15, both under pre-arranged Rule 10b5-1 trading plans. While such sales are routine, they occurred at prices substantially above where the stock currently trades. Meanwhile, institutional activity was mixed — Dimensional Fund Advisors boosted its position by 28.1%, while Harel Insurance Investments cut its stake by 99.6%.

On the positive side, Benchmark initiated coverage with a Buy rating and a $570 price target on July 15, and Goldman Sachs highlighted Synopsys as a key beneficiary of the structural chip-design engineer shortage with a $600 price target. However, these bullish calls were insufficient to counter the overwhelming selling pressure.

What Drove SNPS Stock Performance Over the Last Quarter

The broader quarterly decline reflects a market that has grown more cautious about Synopsys' post-Ansys integration trajectory. While the acquisition substantially expanded the company's total addressable market and delivered eye-catching revenue growth of approximately 42% year-over-year, reported GAAP profitability has been compressed by integration costs, amortization of acquired intangibles, and deal-related charges. GAAP net income for Q2 was just $17.1 million, versus $349.2 million a year earlier, while GAAP EPS of $0.09 contrasted sharply with the non-GAAP figure of $3.35. This wide gap between GAAP and non-GAAP results has fueled debate about the true earnings power of the combined entity.

Additionally, management's commentary around "agentic AI" — AI systems that run Synopsys software alongside human engineers — signals a potentially transformative but unproven pricing model shift. CEO Sassine Ghazi described at the Mizuho Technology Conference a future where the company charges not just for human user subscriptions but for AI agent usage as well. While strategically compelling, this transition introduces complexity into revenue visibility at a time when investors are demanding clearer evidence that the Ansys deal will deliver the promised cross-selling synergies and margin expansion. The upcoming Investor Day on September 30 is widely expected to provide more clarity on these long-term targets.

SNPS Stock Forecast Drivers: What Investors Should Watch Next

Investors will be closely monitoring Synopsys' fiscal Q3 2026 earnings, expected in late August, for evidence that the IP licensing business is stabilizing and that full-year guidance can be revised materially higher. The company's September 30 Investor Day represents a critical catalyst, where management is expected to lay out long-term financial targets and elaborate on the AI-agent pricing model and Ansys synergy roadmap. Macroeconomic risks remain salient, including potential changes to U.S. export controls affecting China-exposed revenue (approximately 10% of total sales), geopolitical instability, and the trajectory of semiconductor R&D budgets in an environment of elevated trade tensions. On the competitive front, the duopoly with Cadence Design Systems remains stable, but the growing trend of hyperscale customers building custom chips in-house could reshape demand patterns over time. Technical traders will be watching whether deeply oversold RSI readings near 22 translate into a mean-reversion rally or whether structural concerns continue to drive price discovery lower.

Using AI Tools in My Research Process

During volatile stretches like this one for SNPS, I have found it helpful to review automated strategies for additional context. Tickeron’s Trending AI Robots page highlights top-performing bots with distinct strategies and performance metrics, offering a practical way to explore data-driven approaches that align with different investment objectives.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations
Related Ticker: SNPS

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


SNPS's RSI Indicator climbs out of oversold territory

The RSI Indicator for SNPS moved out of oversold territory on July 31, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 24 similar instances when the indicator left oversold territory. In of the 24 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 31, 2026. You may want to consider a long position or call options on SNPS as a result. In of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for SNPS just turned positive on July 31, 2026. Looking at past instances where SNPS's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SNPS advanced for three days, in of 346 cases, the price rose further within the following month. The odds of a continued upward trend are .

SNPS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The 50-day moving average for SNPS moved below the 200-day moving average on July 30, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNPS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for SNPS entered a downward trend on July 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. SNPS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.550) is normal, around the industry mean (23.996). P/E Ratio (92.902) is within average values for comparable stocks, (75.895). Projected Growth (PEG Ratio) (2.179) is also within normal values, averaging (1.870). SNPS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.021). P/S Ratio (8.576) is also within normal values, averaging (132.177).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNPS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Microsoft Corp (NASDAQ:MSFT), Oracle Corp (NYSE:ORCL), Palo Alto Networks Inc (NASDAQ:PANW), Crowdstrike Holdings Inc (NASDAQ:CRWD), Block Inc (NYSE:XYZ), NetApp (NASDAQ:NTAP), MongoDB (NASDAQ:MDB), Twilio (NYSE:TWLO), Zscaler (NASDAQ:ZS), Okta (NASDAQ:OKTA).

Industry description

Computer communications industry develops technology that allows computing devices to exchange data with each other using connections/data links between nodes. Common types of computer network include Cloud (IAN), Internet, Wide (WAN, Local (LAN)/Wireless(WLAN) etc. The industry is an ever-more important part of technology, and is set to become even bigger as the Internet of Things (IoT) rapidly forays into the various aspects of our lives. Cisco Systems, Inc., Palo Alto Networks, Inc. and Arista Networks, Inc., Fortinet, Inc. are some of the major computer communications companies.

Market Cap

The average market capitalization across the Computer Communications Industry is 34.65B. The market cap for tickers in the group ranges from 48.8K to 3.71T. MSFT holds the highest valuation in this group at 3.71T. The lowest valued company is WMHI at 48.8K.

High and low price notable news

The average weekly price growth across all stocks in the Computer Communications Industry was 4%. For the same Industry, the average monthly price growth was -4%, and the average quarterly price growth was 19%. WETO experienced the highest price growth at 92%, while CSAI experienced the biggest fall at -97%.

Volume

The average weekly volume growth across all stocks in the Computer Communications Industry was -10%. For the same stocks of the Industry, the average monthly volume growth was -15% and the average quarterly volume growth was -48%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 46
P/E Growth Rating: 72
Price Growth Rating: 56
SMR Rating: 80
Profit Risk Rating: 92
Seasonality Score: -6 (-100 ... +100)
View a ticker or compare two or three
SNPS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a developer of software based designing solutions for the semiconductor industry

Industry ComputerCommunications

Profile
Details
Industry
Packaged Software
Address
675 Almanor Avenue
Phone
+1 650 584-5000
Employees
28000
Web
https://www.synopsys.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.